Dexcom's CGM and Abbott's FreeStyle Libre are ... CGMs consist of a sensor, a transmitter, and a receiver. The sensor is ...

DexCom's stock has declined 35% since my last bearish article, validating my "Sell" rating, though past bearish calls were incorrect as the stock previously doubled and tripled. Q3 results showed ...

Starting today, Dexcom G7 continuous glucose monitor (CGM) users will be able to monitor their real-time blood sugar data ...

In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other high growth large cap stocks. BlackRock highlighted that its portfolio managers are broadly ...

DexCom will likely make significant headway in its addressable market in the next five years. The company should also increase its reach by launching new products and entering new countries ...

Oct 24 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat Wall Street estimates for third-quarter revenue and profit on Thursday, helped by resilient demand for its continuous ...

DexCom (DXCM) reported $994.2 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 2%. EPS of $0.45 for the same period compares to $0.50 a year ago.

Analyst Patrick Wood from Morgan Stanley maintained a Hold rating on Dexcom (DXCM – Research Report) and keeping the price target at $75.00. Patrick Wood has given his Hold rating due to a ...

DexCom reports quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 43 cents. Quarterly revenue comes in at $994.2 million, which beat the analyst consensus ...